tirzepatide help with inflammation mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular Tirzepatide and Cardiovascular Outcomes: A

Tirzepatide is different from a standard GLP-1-only medicine because it is a long-acting dual agonist that acts on both the GIP receptor and the GLP-1 receptor

Transplantation of pluripotent stem cells Recent advancements in the understanding of cardiac regeneration mechanisms have elevated regenerative cardiology to a field of paramount importance, offering the potential to restore cardiac function and improve patient outcomes

Interventional Agnostic Trials: Conducting randomized clinical trials to evaluate whether targeted adjunctive microbiota modulations (probiotics, prebiotics, or postbiotics) can synergistically enhance GLP-1 RA efficacy or mitigate weight regain after drug discontinuation

Jamie Justice Longevity by Design is a podcast for individuals looking to experience longer, healthier lives

31, 2025 (GLOBE NEWSWIRE) -- Truvetas groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open , offering critical insights into GLP-1 discontinuation and reinitiation rates, and the roles income, adverse events, and weight changes may play